FDA Approves Rituxan® for Treatment of CLL (2/23/2010)
On February 18, 2010 the U.S. Food and Drug Administration (FDA) announced the approval of Rituxan® (rituximab) for the treatment of patients with chronic lymphocytic leukemia (CLL).

Revlimid® and Rituxan® Safe and Effective for Therapy of Relapsed CLL (1/6/2010)
Researchers from the M. D. Anderson Cancer Center have reported that Revlimid® (lenalidomide) and Rituxan® (rituximab) is a safe and effective regimen for treatment of patients with relapsed chronic lymphocytic leukemia (CLL). The details of this study were presented at the 2009 meeting of the American Society of Hematology in New Orleans in the first week of December.

Treanda® and Rituxan® Effective First-line Therapy for CLL (1/6/2010)
Researchers affiliated with the German CLL Study Group (GCLLSG) have reported that Treanda® (bendamustine) and Rituxan® (rituximab) is effective and safe for initial treatment of patients with advanced chronic lymphocytic leukemia (CLL). The details of this Phase II study were presented at the 2009 meeting of the American Society of Hematology in New Orleans in early December.

Ofatumumab, Fludara®, Cytoxan® Regimen Highly Effective for Initial Treatment of CLL (1/5/2010)
Researchers involved in an international multicenter clinical trial have reported that a regimen of ofatumumab, Fludara® (fludarabine), and Cytoxan® (cyclophosphamide) (O-FC) is highly active for the initial treatment of patients with symptomatic chronic lymphocytic leukemia (CLL). The details of this study were presented at the 2009 meeting of the American Society of Hematology in New Orleans in early December.

Danusertib, a Multi-Kinase Aurora Inhibitor, Promising for Treatment of CML Refractory to First- and Second-generation Kinase Inhibitors (12/28/2009)
Researchers involved in an international multicenter Phase I study have reported that danusertib (PHA-739358) produces responses in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) who have failed treatment with Gleevec® (imatinib), Sprycel® (dasatinib), and Tasigna® (nilotinib). The details of this study were presented at the 2009 meeting of the American Society of Hematology (ASH) in New Orleans in early December.